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Modulation of the Cell Membrane 
Expression of the Kininogens 
Regulates the Rate of Bradykinin 
Delivery to Cells 
Alvin H. Schmaier 
The kininogens were first recognized as the parent molecules for 
bradykinin. Their relative physiologic importance in plasma hemosta- 
sis and fibrinolysis and tissue cysteine protease inhibition has not been 
clan-fed. Recent studies on the structure and function of the plasma 
kininogens, their interaction with cells of the intravascular compart- 
ment, and clinical investigations on contact system activation have 
refocused the physiologic importance of these proteins to kinin delivery 
for the maintance of vasodilatovy tone. Kininogen expression on 
platelets slows the rate of kinin liberation, and kinins upregulate 
kininogen expression on endothelial cells. Regulation of kinin delivery 
by influencing kininogen expression may provide for new agents to 
manipulate blood pressure. (Trends Cardiovasc Med 1992;2:108-114) 
The particular physiologic role of the activate the fibrinolytic system, and in- 
proteins of the contact system of plasma fluence blood pressure. Although much 
proteolysis has been elusive. Activation work has been performed over the last 15 
of the proteases of this system has been years, little progress has been made in 
reported to initiate intrinsic coagulation, understanding this system in hemostasis 
and fibrinolvsis. Deficiencies of the zv- 
Alvin H. Schmaier is at the Division of 
Hematology and Oncology, Department of 
mogens of this system, factor XII (Hage- 
Internal Medicine, Simpson Memorial Re- 
man factor) and prekallikrein (Fletcher 
search Institute, University of Michigan, Ann factor), or their cofactor/substrate, high- 
Arbor, MI 48109-0724, USA. molecular-weight kininogen (Fitzgerald 
or Williams factor) give rise to striking 
abnormal procoagulant states in vitro 
but no corresponding clinical bleeding 
states. The absence of any hemostatic 
defect suggests no direct role for these 
proteins in hemostasis. This interpreta- 
tion is supported by recent work show- 
ing that in the presence of negatively 
charged surfaces, such as sulfatides and 
dextran sulfate, thrombin is a better 
activator of factor XI, the first commit- 
ted protein of the hemostatic system, 
than activated forms of factor XII (Naito 
and Fujikawa 1991; Gailani and Broze 
1991). Similarly, the role of this system 
in fibrinolysis needs better definition. 
Activated forms of factor XII, prekal- 
l&rein, and factor XI have all been 
shown to activate plasminogen to plas- 
min, but this entire system is at best 
l/10,000 as potent as the endogenous 
tissue and urokinase plasminogen acti- 
vator systems. Alternatively, desamino 
a-arginine vasopressin-induced plasmin- 
ogen-activating activity is partially de- 
pendent on the contact system since it is 
impaired in factor-XII-deficient individ- 
uals (Levi et al. 1991). 
Even though little progress has been 
made in understanding the contact sys- 
tem’s role in hemostasis and fibrinolysis, 
significant progress has been made in 
understanding the structure and func- 
tion of high-molecular-weight kininogen 
(HK), the main cofactor and substrate of 
this system. Investigations on HK and 
the other plasma kininogen, low-molec- 
ular-weight kininogen (LK), indicate roles 
for these proteins in local blood pressure 
regulation and possibly fibrinolysis. The 
first recognized function of the plasma 
kininogens was to serve as the parent 
protein for the potent vasoactive peptide, 
bradykinin (BK). Recent laboratory stud- 
ies on the interaction of the kininogens 
with cells in the vascular compartment 
and clinical investigations have allowed 
for a reorientation of interest back to the 
kinin delivery function of the kininogens 
and, in turn, a refocusing on the signifi- 
cance of the proteases of this system that 
serve as kininogenases. This review sum- 
marizes recent information on the kinin- 
ogens’ structure and function and their 
interaction with cells. This information 
will suggest an important physiologic 
activity for these proteins and their 
regulating proteases in the maintenance 
and modulation of blood pressure home- 
ostasis. 
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l Structure and Function of the 
Kininogens 
Both kininogens, HK and LK, are pro- 
duced by a single gene (Takagaki et al. 
1985) that maps to chromosome 3 (Fong 
et al. 1991). This single gene of 11 exons 
and 27 kilobases (kb) produces a unique 
mRNA for each kininogen by alternative 
splicing (Kitamura et al. 1985). HK and 
LK share the coding region of the first 
nine exons and a part of exon 10 contain- 
ing the bradykinin sequence and the first 
12 amino acids after the carboxy- 
terminal portion of bradykinin. Exon 11 
codes for the unique 4-M) light chain of 
LK. The complete exon 10 contains the 
full coding region for the unique 56-kD 
light chain of HK. By alternative RNA 
processing events, HK is produced from 
exon 10. In the rat kininogen gene, a 
novel mechanism occurs for alternative 
RNA processing (Kakizuka et al. 1990). 
Splicing efficiency is controlled by the 
interaction of Ul small nuclear ribonu- 
cleoproteins and the Ul snRNA-comple- 
mentary repetitive sequences of the ki- 
ninogen pre-mRNA. The mRNA for LK 
and HK are 1.7 and 3.5 kb, respectively. 
The two mR.NAs of the kininogens 
code for two separate proteins. LK is a 
66-kD P-globulin with a plasma concen- 
tration of 160 pg/mL (Schmaier et al. 
1986a). HK is a 120~kD a-globulin with a 
plasma concentration of 80 pg/mL (Sch- 
maier et al. 1983). Both kininogens have 
a common 64-kD so-called heavy chain, 
the BK sequence, and the 12 amino acids 
after the carboxy terminus of BK. The 
common heavy chain of both kininogens 
consists of three domains (Salvesen et al. 
1986). Domain 1 of the heavy chain has a 
low-affinity calcium-binding site whose 
function has yet to be characterized 
(Ishiguro et al. 1987). Domains 2 and 3 
contain the highly conserved amino acid 
sequence QWAG found in cysteine pro- 
tease inhibitors. Both LK and HK are 
potent, tight-binding, reversible cysteine 
protease inhibitors with Kis of 2 and 0.5 
nM, respectively, against human platelet 
calpain (Bradford et al. 1990). Until its 
cloning, LK was also known as a,- 
cysteine protease inhibitor. Although both 
domains 2 and 3 are inhibitors of most 
cysteine proteases, domain 2 of the 
kininogens contains the inhibitory area 
for calpains, calcium-activated cysteine 
proteases (Schmaier et al. 1987). Since 
most cysteine proteases are intracellular, 
a function of the kininogens may be to 
act as a cell membrane regulator of these 
proteins when they become externalized 
upon cell activation (Schmaier et al. 
1990). 
Both kininogens are parent proteins 
for BK. LK is a better substrate for tissue 
kallikreins to liberate lys-BK; HK is a 
better substrate for plasma kallikrein to 
liberate BK. Elastase treatment of LK 
facilitates the liberation of BK and met-lys- 
BK by plasma kallikrein (Sato and Na- 
gasawa 1988). Alternatively, elastase pro- 
teolyses the light chain of HK and 
destroys its procoagulant activity (Kleni- 
ewski and Donaldson 1988). Likewise, 
human cathepsin D inactivates the cys- 
teine protease inhibitory activity of the 
kininogens by proteolyzing domain 3 
(Lenarcic et al. 1991). A wide range of 
bacterial proteases are also able to liber- 
A WIDE RANGE OF BACTERIAL 
PROTEASES ARE ABLE TO LIBERATE 
KININS, SUGGESTING THAT THE 
HYPOTENSION OFTEN SEEN IN 
SEPSIS MAY BE DUE TO A DIRECT 
EFFECT OF THE INFECTING 
ORGANISM’S PROTEASES IN 
LIBERATING KININS. 
ate kinins, suggesting that the hypoten- 
sion often seen in sepsis may be due to a 
direct effect of the infecting organism’s 
proteases in liberating kinins (Akhteruz- 
zaman et al. 1989). 
The 56-kD light chain of HK has the 
unique property to serve as a cofactor in 
the activation of factor XII, prekallikrein, 
and factor XI. The procofactor activity of 
HK results from the functional activity 
of the two domains that compose the 
light chain of HK. Domain 5 is a histidine- 
and glycine-rich region that has the 
ability to bind to anionic surfaces. This 
region contains a zinc-binding site of 
high affinity such that HK can be puri- 
fied on zinc chelate chromatography 
(Retzio et al. 1987). The zinc-binding 
region on HK’s domain 5 can also 
function to decrease the heparin-en- 
hancing inhibitory effect of antithrom- 
bin III on cx-thrombin (Bjork 1989). 
Domain 6 of the light chain of HK 
contains the factor-XI- and prekallikrein- 
binding sites (Tait and Fujikawa 1986; 
Vogel et al. 1990). The prekallikrein- and 
factor-XI-binding site is contained within 
a 31-residue peptide that contains pre- 
dominantly p-turn elements (Scarsdale 
and Harris 1990). The procoagulant ac- 
tivity of HK depends upon intact func- 
tioning of these two domains of the 
protein. Firstly, a region on domain 5 of 
HK must bind to anionic surfaces; sec- 
ondly, another region on domain 6 of I-IK 
must form complexes with prekallikrein 
and factor XI. Blockage of either interac- 
tion with monoclonal antibodies directed 
to these regions will inhibit HK’s proco- 
agulant activity (Schmaier et al. 1987; 
Reddigari and Kaplan 1989). 
l The Interaction of the Kininogens 
with Cells of the Vascular 
Compartment 
HK has been found to be contained in 
platelet cl-granules, and ~8% of total 
platelet HK is plasma HK tightly bound 
and nonexchangeable with the platelet 
membrane (Schmaier et al. 1983 and 
1986b). Upon platelet activation, 40% of 
the total amount of platelet HK is se- 
creted and another 40% of the total 
amount of platelet HK becomes ex- 
pressed upon the activated platelet mem- 
brane (Figure 1). The total platelet con- 
tribution of HK to plasma HK is only 
0.23%. Since platelets secrete their gran- 
ule content by exocytosis, however, the 
local concentration of HK on or about 
the activated platelet surface may exceed 
ten times the plasma concentration of 
this protein. Unstimulated and activated 
platelets have unoccupied binding sites 
for HK (Gustafson et al. 1986; Greengard 
and Griffin 1984). The affinity of the 
kininogens to bind to unstimulated and 
activated platelets is the same. Human 
platelets also have high-affinity binding 
sites for low-molecular-weight kininogen 
(Meloni and Schmaier 1991). LK and 
HK are mutually competitive in binding 
to the unstimulated platelet surface. 
Both HK and LK bind to the platelet 
surface as intact proteins. 
Human granulocytes contain HK and 
have high-affinity, unoccupied binding 
sites for HK (Gustafson et al. 1989a). HK 
serves as a noncompetitive inhibitor of 
fibrinogen binding to granulocytes (Gus- 
tafson et al. 1989b). OKMl, which is a 
monoclonal antibody to the leukocyte 
integrin CD lib/CD 18 (MACl), blocks 
fibrinogen binding to granulocytes, but 
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Figure 1. Kininogen-platelet interactions. HK, high-molecular-weight kininogen; LK, low-molecular- 
weight kininogen; BK, bradykinin; lys-BK, lys-bradykinin; HVK, human urinary kallikrein; 
KAL, plasma kallikrein; KFHK, kinin-free high-molecular-weight kininogen; TSP, throm- 
bospondin; PF4, platelet-factor 4; Ilu, a-thrombin; XI, factor XI; Xla, activated factor XJ; and 
PPACK-ZZu, a-phenylalanyl-prolyl-arginine chloromethyl ketone-treated a-thrombin. HK is 
contained in platelet a-granules. Upon stimulation of platelets by any agonist, platelet HK is 
secreted from platelet a-granules into the suspension media. In addition to secretion of platelet 
HK, a portion of equal amount to secreted platelet HK is expressed upon the activated platelet 
membrane. The unstimulated platelet also contains unoccupied binding sites for HK or LK. 
Platelet-bound HK serves as a binding site for factors XI and XIa. Platelet-bound HK or LK can 
block a-thrombin. but not PPACK-thrombin, from binding to its high-affinity site. Platelet- 
bound HK and LK are substrates for plasma and tissue kallikrein to release bradykinin or 
lys-bradykinin. respectively, and leave kinin-free HK or LK, respectively, bound to the platelet 
surface. 
does not block HK binding (Figure 2). tutively expressed pool of HK mRNA 
Granulocyte-bound HK is proteolyzed (Van Iwaarden et al. 1988a; Schmaier et 
by elastase. Human umbilical vein endothe- al. 1988). Human umbilical vein endo- 
lial cells in culture are able to adsorb HK thelial cells also contain high-affinity 
from their media and are also able to binding sites for HK (Van Iwaarden et al. 
synthesize the protein from their consti- 1988b; Schmaier et al. 1988) and LK 
Figure 2. High-molecular-weight kininogen-granulocyte interactions. Fb, fibrinogen; and 
elastase, human neutrophil elastase. All other abbreviations are defined in the Figure 1 legend. 
HK is contained in total lysates of well-washed granulocytes. It can also bind to unoccupied 
binding sites on the granulocyte surface. Membrane-expressed HK could serve as a 
kallikrein-binding site. Membrane-bound HK serves as a noncompetitive inhibitor of 
fibrinogen binding to granulocytes. OKM 1 blocks fibrinogen binding to granulocytes, but does 
not block HK binding to granulocytes. Granulocyte HK participates in allowing the full extent 
of its elastase secretion induced by plasma kallikrein. 
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(Zini et al. 1991). Bradykinin through 
protein kinase C is able to upregulate 
HK- and LK-binding sites on endothelial 
cells. Endothelial cells may have unique 
binding sites for HK’s light chain and 
kininogen’s heavy chain since phorbol 
esters alone only increase the former and 
calcium ion and phorbol esters only 
upregulate the latter (Zini et al. 1991). 
HK binds to the endothelial cell surface 
as an uncleaved protein. Endothelial cell 
membrane-bound HK has the potential 
to deliver bradykinin, which can stimu- 
late the release of a number of metabolic 
products (Figure 3). HK binds to plate- 
lets, granulocytes, and endothelial cells 
with similar affinity (Table 1). Since the 
affinity of HK binding to cells in the 
intravascular compartment is 1 O-52 nM, 
and the plasma concentration of HK is 
670 nM, we can postulate that all kinino- 
gen-binding sites in the intravascular 
compartment are saturated in vivo. The 
number of binding sites for the kinino- 
gens on cells in the intravascular com- 
partment varies as to the cell. Platelets 
have -1000 binding sites/cell; granulo- 
cytes, SO,OOO/cell; and endothelial cells 
-1,000,OOO sites/cell (Table 1). However, 
if one calculates the density of distribu- 
tion of HK-binding sites per unit of 
surface area, each of these cells found 
within the intravascular compartment 
has about the same density of distribu- 
tion of kininogen-binding sites per unit 
of surface area. This finding suggests 
that the availability of kininogen sub- 
strate for kinin delivery is equally distrib- 
uted on platelets, granulocytes, and en- 
dothelial cells in the intravascular com- 
partment. 
l Domains of the Plasma Kininogens 
That Participate in Cell Membrane 
Binding 
It has been a common understanding 
to investigators in the field that since HK 
contains a region on its light chain that 
binds to anionic surfaces, any interac- 
tion of HK with cells, a physiologic 
surface, must also be proceeding 
through its 56-kD light chain. However, 
the finding that LK specifically binds to 
platelets and functions as a mutual 
competitor of HK binding to platelets 
suggests that there must be a region of 
the heavy chain of the kininogens that 
contains a cell-binding domain (Table 1) 
(Meloni and Schmaier 1991). Accord- 
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ingly, the isolated heavy chain of HK 
inhibits HK binding to platelets (Meloni 
et al. 1992). However, LK or the purified 
light chain of HK are not mutual compe- 
titors of the other binding to platelets. 
Monoclonal antibodies directed to do- 
main 3 (D3) on kininogens’ heavy chain 
inhibited [i2sI]HK from binding to plate- 
lets (Jiang et al. 1992). Further, isolated 
D3 from the heavy chain of the kinino- 
gens was found to bind specifically to the 
unstimulated platelet surface and human 
umbilical vein endothelial cells. D3 bind- 
ing to platelets is reversible and satura- 
ble (Table 1). D3 can function as a 
competitor of either HK or LK binding to 
platelets. Unlike HK and LK, which both 
require zinc ion for binding, D3 does not 
need zinc to bind to platelets. Since both 
HK and LK require zinc ion in order to 
bind to platelets, the role of this divalent 
cation must be on the expression of the 
putative kininogen receptor(s) on plate- 
lets, similar to the role of zinc ion for 
conformational changes of the human 
growth hormone receptor for growth 
hormone binding. D3 being a smaller 
protein may be able to insert into its site 
without the receptor having the neces- 
sary conformational changes for binding 
of the larger proteins. 
Although D3 on the heavy chain of the 
plasma kininogens contains a cell- 
binding site, it is not the exclusive 
cell-binding domain for HK. The puri- 
fied 56-kD light chain of HK has the 
ability to inhibit [t251]HK, but not [i251]LK, 
from binding to platelets. The [1251]56- 
kD light chain of HK can directly bind to 
the platelet surface (Meloni et al. 1992). 
The [1251] light chain of HK binding to 
platelets is specific because it is blocked 
by the unlabeled light chain, HK, EDTA, 
or no zinc, but it is not inhibited by LK or 
unrelated plasma proteins. These data 
indicate that two domains on HK partici- 
pate in platelet binding: one on its heavy 
chain and another on its light chain 
(Figure 4). 
l Significance of the Cellular 
Expression of the Plasma 
Kininogens 
Kininogens on platelets and granulocytes 
have been shown to have a number of 
functions. Platelet-bound HK serves as a 
binding site for factor XFXIa (Green- 
gard et al. 1986; Sinha et al. 1984). The 
function of platelet-bound FXI/XIa has 
EDRF 
rHK+-HKl 
Figure 3. High-molecular-weight kininogen-endothelial cell interactions. EDRF, endothelial-cell- 
derived relaxing factor or nitric oxide: tPA, tissue plasminogen activator; PGZ,, prostacyclin; 
XZZa, activated factor XII; and XZZp Hageman factor fragment. All other abbreviations are 
defined in the Figure 1 legend. Human umbilical vein endotbelial cells grown in culture contain 
unoccupied binding sites for HK. These endotbelial cells contain HK antigen and have a high 
constitutive expression of HK mRNA. Theoretically, bradykinin liberated from soluble or 
cell-bound kininogen can stimulate these prostaglandin synthesis systems to stimulate 
prostacyclin production. Bmdykinin from kininogen can also stimulate EDRF release and tPA 
production. 
yet to be clarified, since cell-bound fac- 
tor XIa is not a better activator of factor 
IX than unbound factor XIa. HK serves 
as a noncompetitive inhibitor of the 
cytoadhesion function of fibrinogen on 
granulocytes and activated platelets, but 
not on unstimulated platelets (Gustafson 
et al. 1989b). The relative importance of 
this effect needs to be clarified, but it 
could be important in modifying fibrino- 
gen or other adhesive glycoproteins’ 
interactions with cells. Granulocyte HK 
also serves as a cofactor for the full 
expression of kallikrein-induced elastase 
secretion, probably by serving as an 
additional receptor for kallikrein (Gus- 
tafson et al. 1989a). Platelet-bound HK 
or LK could serve as a membrane- 
localized inhibitor of calpain when cal- 
pain is expressed upon the activated 
platelet surface (Schmaier et al. 1990; 
Pm-i et al. 1991). This mechanism could 
be important in limiting the extent of 
glycocalicin liberation horn glycopro- 
tein Ib and in modulating the exposure 
of the fibrinogen receptor by extemal- 
ized calpain. 
Platelet membrane-expressed kinino- 
gens also have the ability to inhibit 
thrombin-induced platelet aggregation 
and secretion (Meloni and Schmaier 
1991). Initially, this effect was thought to 
be due to the ability of membrane-bound 
kininogens to inhibit externalized plate- 
Table 1. Kininogen expression on cells 











27+2 647 f 147 
39 k 8 1227 f 404 
10 f 1.3 4.8 x 104 
52+13 9.3 x 105 
43f8 9.7 x 105 
0 The numbers presented represent direct binding to the radioligand to the indicated cell. 
b The abbreviations used in this column are as follows: HK, high-molecular-weight kininogen; LK, 
low-molecular-weight kininogen; and 03, domain 3 of the heavy chain of the plasma kininogens. 
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Figure 4. Structure and function of high-molecular-weight kininogen. HC, heavy chain of the 
kininogens; and LC. light chain of HK. All other abbreviations arc explained in the Figure 1 
legend. High-molecular-weight kininogen is divided into six dom&ns. Domains l-3 @I-03) 
are the so-called heavy chain of the plasma kininogens. Domain 1 contains a low-affinity 
calcium-binding site. Both domains 2 and 3 contain a highly conserved amino acid sequence, 
QWAG, which is contained in most cysteine protease inhibitors. Uniquely, domain 2 inhibits 
the calcium-activated cysteine protease, calpain. Domain 3 has been found also to contain a 
cell-binding region and another epitope that contains a region inhibitory to thrombin binding 
to platelets. Domain 4 (04) is the bradykinin sequence. Domain 5 (05) is an HG-rich region that 
binds zinc and binds to anionic surfaces. Domain 6 (06) contains the prekallikrein- and 
factor-XI-binding region. There is another cell-binding region on the light chain of HK, but it is 
unclear as of yet as to whether it is contained on domain 5 or domain 6 of the kininogens. 
let calpain. However, the finding that 
both HK and LK inhibited platelet secre- 
tion independent of platelet aggregation 
indicated that the kininogens influenced 
the interaction of thrombin with plate- 
lets in a more fundamental manner. 
Both HK and LK were found to be 
noncompetitive inhibitors of a-thrombin 
binding to its receptor. The kininogens 
do not complex with a-thrombin, or 
inhibit the proteolytic activity of throm- 
bin, or inhibit an amino-terminus pep- 
tide of the thrombin receptor horn activat- 
ing platelets (Meloni and Schmaier 199 1; 
Jiang et al. 1992). Further, the kinin- 
ogens do not bind to thrombin’s binding 
site on platelets because they do not 
inhibit n-phenylalanyl-prolyl-arginine 
chloromethyl ketone-treated ol-thrombin 
from binding to platelets. D3 of the 
kininogens’ heavy chain functions as a 
thrombin inhibitor similar to the intact 
protein. It appears that the thrombin- 
inhibitory region on D3 is a distinct 
epitope from its cysteine protease- 
inhibitory and cell-binding areas (Jiang 
et al. 1992) (Figure 4). 
In addition to the above influences of 
the kininogens on platelet and granulo- 
cyte function, platelet-bound HK influ- 
ences plasma proteolysis. The rate by 
which platelet-bound HK is proteolyzed 
by 1% plasma kallikrein or tissue kal- 
likrein is much slower than the rate of 
proteolysis of soluble I-IK or platelet- 
bound HK that elutes off the platelet 
surface (Meloni et al. 1992). Both plasma 
and tissue kallikrein cleave HK such that 
bradykinin or lys-bradykinin are liber- 
ated. Thus, platelet binding of kininogen 
decreases the rate by which bradykinin 
can be liberated from kininogens. These 
data suggest that cell-bound kininogen is 
protected from kinin liberation. The 
significance of this finding is discussed 
in the following sections. 
l Physiologic Importance of 
Activation of the Contact System of 
Plasma Proteolysis 
It has been argued that the importance 
of the plasma LK and HK cannot simply 
reside in 1.6% and 0.8%, respectively, of 
their molecular mass. However, it is 
equally cogent to argue that the design of 
these proteins is exclusively for kinin 
delivery to areas where it will be most 
effective. This latter hypothesis is sup- 
ported by a wealth of clinical data 
ascertaining the significance of plasma 
contact system activation. Factor XII 
activation during the preparation of a 
plasma protein fraction resulted in a 
product that induced hypotension upon 
infusion (Alving et al. 1978). Although 
activation of the contact system is pur- 
ported to activate the coagulation sys- 
tem, a study of adult respiratory distress 
syndrome induced by either sepsis or 
trauma showed profound activation of 
the contact system with little activation 
of prothrombin (Carvalho et al. 1988). 
Alternatively, early Rocky Mountain spot- 
ted fever, an archetypal endothelial cell 
injury disorder, was associated with 
profound thrombin formation and plate- 
let activation with little contact system 
activation (Rao et al. 1988). These two 
investigations indicate that activation of 
the contact system is independent of 
activation of the hemostatic system and 
vice versa. This interpretation is sup- 
ported by the clarification of the impor- 
tance of the tissue factor-factor VII 
system in activating factor X directly or 
indirectly through factor IX activation. 
Alternatively, in patients with sepsis, the 
degree of activation of the contact sys- 
tem correlated with the observed degree 
of hypotension (Kaufman et al. 1991). 
These studies suggest that activation of 
the contact system is mostly associated 
with hypotension and vascular instabil- 
ity. Formation of the plasma enzymes of 
the contact system results in the libera- 
tion of bradykinin from its substrate 
kininogens. The multidomain nature of 
the kininogens can be interpreted as 
highly refined bradykinin delivery sys- 
tems. HK can bind to cells by two 
portions to bring its kininogenases kal- 
likrein and factor XIa to cell surfaces to 
liberate externalized bradykinin from its 
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parent molecule. Its cysteine-protease- 
inhibitory domain could prevent tissue 
cysteine proteases from totally lysing the 
protein (Schmaier et al. 1986b). The 
thrombin-inhibitory domain on kinino- 
gens could serve to limit thrombin bind- 
ing to cells to decrease thrombin’s ability 
to activate factor Xl and cleave HK to 
possibly liberate more kinin (Naito and 
Fujikawa 199 1; Gailani and Broze 199 1). 
l Role of the Kininogens in the 
Modulation of Blood Pressure 
Bradykinin has profound effects on 
the vascular endothelium. It stimu- 
lates inositol phosphate production in 
these cells to induce prostacyclin syn- 
thesis and superoxide formation (Hong 
1980; Lambert et al. 1986; Holland et 
al. 1990). It also stimulates the release 
of tissue plasminogen activator in vivo 
(Smith et al. 1983) and nitric oxide or 
endothelium-derived relaxing factor 
(EDRF) (Palmer et al. 1987). Clinical 
states associated with bradykinin eleva- 
tion, such as sepsis, are characterized 
by hypotension. Agents such as angio- 
tensin-converting enzyme (ACE) inhib- 
itors that inhibit one of the enzymes 
(kininase II or ACE) that proteolyze 
bradykinin are potent afterload re- 
ducers and antihypertensives. It is 
reasonable to hypothesize that any 
agent that modifies delivery of bradyki- 
nin to the endothelium will modify its 
influence on vascular tissue. Since the 
kininogens, HK and LK, are the parent 
molecules of bradykinin or its deriva- 
tives, any modification of their expres- 
sion on cells in the intravascular com- 
partment should alter the availability 
of the substrate for kinin formation. 
Thus, blocking kininogen binding to 
cells by a peptide directed to its cell- 
binding domain could influence the 
degree of cell-bound kininogen. Simi- 
larly, regulating the putative receptor(s) 
for the kininogens on cells in the 
intravascular compartment could mod- 
ulate the amount of bound kininogen. 
Since a number of kininases in addi- 
tion to ACE are transmembrane and 
plasma proteins, the notion has arisen 
that physiologically influential bradyki- 
nin must be that which arises in a 
protected milieu. Although our studies 
with platelets indicate that platelet- 
bound kininogen has delayed bradyki- 
nin liberation in comparison to solu- 
ble kininogen, it has yet to be deter- 
mined whether physiologic, vasoregu- 
latory bradykinin is derived from cell- 
bound or soluble kininogen. Ascer- 
taining the locus of physiologic bradyki- 
nin liberation will be a key step in 
understanding the role of this peptide 
in the autocrine regulation of vascular 
tone. Modulating the cell binding of 
kininogens by blocking its receptor or 
downregulating the receptor(s)’ expres- 
sion could be a new means to regulate 
blood pressure homeostasis. 
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